Trial Profile
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Razuprotafib (Primary) ; Ranibizumab
- Indications Diabetic macular oedema
- Focus Proof of concept; Therapeutic Use
- Acronyms TIME-2
- Sponsors Aerpio Therapeutics
- 02 May 2019 Data from TIME-2 and TIME-2b presented in an Aerpio Pharmaceuticals Media Release.
- 02 May 2019 According to an Aerpio Pharmaceuticals media release, data from TIME-2 and TIME-2b were presented at The Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting.
- 28 Feb 2018 Results published in Aerpio Therapeutics Media Release